{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:27:55Z","timestamp":1787819275489,"version":"build-2784847793"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009845","name":"Ovarian Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA008748"],"award-info":[{"award-number":["CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["OC150111"],"award-info":[{"award-number":["OC150111"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1136\/ijgc-2019-000456","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T14:55:16Z","timestamp":1567004116000},"page":"s16-s21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S2","title":["Novel therapeutics: response and resistance in ovarian cancer"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0161","authenticated-orcid":false,"given":"Dmitriy","family":"Zamarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2019-000456_bb0010","author":"Konstantinopoulos","year":"2018"},{"key":"10.1136\/ijgc-2019-000456_bb0015","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13 Suppl","key":"10.1136\/ijgc-2019-000456_bb0020","article-title":"Phase I study of the alpha specific PI3-kinase inhibitor BYL719 and the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: analysis of the dose escalation and ovarian cancer expansion cohort","volume":"77","author":"Konstantinopoulos","year":"2017","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2019-000456_bb0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000456_bb0030","doi-asserted-by":"crossref","first-page":"111026","DOI":"10.18632\/oncotarget.22195","article-title":"Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer","volume":"8","author":"Brill","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2019-000456_bb0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study","volume":"19","author":"Lee","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2019-000456_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/jfb10010004","article-title":"Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies","volume":"10","author":"Calzoni","year":"2019","journal-title":"J Funct Biomater"},{"key":"10.1136\/ijgc-2019-000456_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9080109","article-title":"Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors","volume":"9","author":"Lim","year":"2017","journal-title":"Cancers"},{"key":"10.1136\/ijgc-2019-000456_bb0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2013.12.001","article-title":"Ovarian cancer stem cells: are they real and why are they important?","volume":"132","author":"Shah","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2019-000456_bb0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/ijgc-2019-000456_bb0060","article-title":"Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways","author":"Bu","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1136\/ijgc-2019-000456_bb0065","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/biom5042589","article-title":"Hsp90: a new player in DNA repair?","volume":"5","author":"Pennisi","year":"2015","journal-title":"Biomolecules"},{"key":"10.1136\/ijgc-2019-000456_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cellsig.2014.11.009","article-title":"The interplay of NR4A receptors and the oncogene-tumor suppressor networks in cancer","volume":"27","author":"Beard","year":"2015","journal-title":"Cell Signal"},{"key":"10.1136\/ijgc-2019-000456_bb0075","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-12-4560","article-title":"TR3 modulates platinum resistance in ovarian cancer","volume":"73","author":"Wilson","year":"2013","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2019-000456_bb0080","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1111\/cas.13771","article-title":"Wnt signaling in human and mouse breast cancer: focusing on Wnt ligands, receptors and antagonists","volume":"109","author":"Yin","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1136\/ijgc-2019-000456_bb0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/156800907780809750","article-title":"Transcription factor NFAT, its role in cancer development, and as a potential target for chemoprevention","volume":"7","author":"Lu","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1136\/ijgc-2019-000456_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091854","article-title":"Targeting tumor adaption to chronic hypoxia: implications for drug resistance, and how it can be overcome","volume":"18","author":"Kim","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ijgc-2019-000456_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/srep33532","article-title":"BG-4, a novel anticancer peptide from bitter gourd (Momordica charantia), promotes apoptosis in human colon cancer cells","volume":"6","author":"Dia","year":"2016","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2019-000456_bb0100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.biocel.2012.02.004","article-title":"MicroRNA-modulated autophagic signaling networks in cancer","volume":"44","author":"Fu","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1136\/ijgc-2019-000456_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/boc.201800050","article-title":"The role of the unfolded protein response in cancer progression: from oncogenesis to chemoresistance","volume":"111","author":"Madden","year":"2019","journal-title":"Biol Cell"},{"key":"10.1136\/ijgc-2019-000456_bb0110","first-page":"2788","article-title":"Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si\u2011SA\u03a4B1 in ovarian cancer","volume":"40","author":"Xiang","year":"2018","journal-title":"Oncol Rep"},{"issue":"15_suppl","key":"10.1136\/ijgc-2019-000456_bb0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5511","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study","volume":"36","author":"Matulonis","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000456_bb0120","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1136\/ijgc-2019-000456_bb0125","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5509","article-title":"Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial","volume":"33","author":"Disis","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000456_bb0130","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-018-0740-8","article-title":"Combination immune checkpoint blockade strategies to maximize immune response in gynecological cancers","volume":"20","author":"Liu","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1136\/ijgc-2019-000456_bb0135","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2019-000456_bb0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008973","article-title":"Ultrahigh dose-rate flash irradiation increases the differential response between normal and tumor tissue in mice","volume":"6","author":"Favaudon","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1136\/ijgc-2019-000456_bb0145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Atlas","year":"2011","journal-title":"Nature"},{"key":"10.1136\/ijgc-2019-000456_bb0150","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1074\/jbc.REV118.002810","article-title":"Recent advances in the structural and mechanistic aspects of hsp70 molecular chaperones","volume":"294","author":"Mayer","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1136\/ijgc-2019-000456_bb0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbcan.2018.07.005","article-title":"ARID1A mutant ovarian clear cell carcinoma: a clear target for synthetic lethal strategies","volume":"1870","author":"Caumanns","year":"2018","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1136\/ijgc-2019-000456_bb0160","doi-asserted-by":"crossref","first-page":"55771","DOI":"10.18632\/oncotarget.9908","article-title":"Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer","volume":"7","author":"Deng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2019-000456_bb0165","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/bph.12978","article-title":"Annexin A2 complexes with S100 proteins: structure, function and pharmacological manipulation","volume":"172","author":"Liu","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1136\/ijgc-2019-000456_bb0170","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3389\/fphar.2018.01367","article-title":"Pin1 in cell cycle control and cancer","volume":"9","author":"Cheng","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1136\/ijgc-2019-000456_bb0175","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1158\/1535-7163.MCT-17-1195","article-title":"Phyllanthusmin derivatives induce apoptosis and reduce tumor burden in high-grade serous ovarian cancer by late-stage autophagy inhibition","volume":"17","author":"Young","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2019-000456_bb0180","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10815-017-0977-4","article-title":"Potential therapeutic applications of human anti-m\u00fcllerian hormone (AMH) analogues in reproductive medicine","volume":"34","author":"Kushnir","year":"2017","journal-title":"J Assist Reprod Genet"},{"key":"10.1136\/ijgc-2019-000456_bb0185","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9025.1","article-title":"EGF receptor ligands: recent advances","volume":"5","author":"Singh","year":"2016","journal-title":"F1000Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24011551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24011551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2019-000456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:10:53Z","timestamp":1753229453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24011551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":36,"alternative-id":["S1048891X24011551"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2019-000456","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutics: response and resistance in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2019-000456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}